Phase I, randomized, placebo controlled, double blind, single dose-escalating study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous IQNLF in healthy subjects.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2011
At a glance
- Drugs IQNLF; IQNLF/IQNPA
- Indications Anthrax
- Focus Adverse reactions
- 26 Apr 2011 IQ Therapeutics completes dosing of 36 volunteers, according to a company media release.
- 26 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to information in an IQ Therapeutics media release.
- 28 Feb 2011 New trial record